Recent advances in bispecific antibody-drug conjugates enhance tumor targeting in breast cancer, indicating promising clinical potential.
BsADCs are a transformative therapeutic modality for breast cancer. Their ability to enhance tumor selectivity, overcome heterogeneity, and target resistant pathways positions them as key players in the future oncology landscape, with ongoing trials poised to define their clinical role.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: